127. Frontotemporal lobar degeneration Clinical trials / Disease details

Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03625128 (ClinicalTrials.gov)	January 2, 2018	12/7/2018	18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls	Phase 0 Evaluation of Clinical and Neuroimage (18F-PM-PBB3 PET) Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls	Alzheimer's Disease;Cortical Basal Syndrome;Frontotemporal Dementia;Progressive Supranuclear Palsy;Vascular Cognitive Impairment	Drug: F-18	Chang Gung Memorial Hospital	NULL	Completed	20 Years	90 Years	All	36	Early Phase 1	Taiwan
2	EUCTR2017-000094-36-SE (EUCTR)	31/03/2017	30/01/2017	The BioFINDER 2 study - improved diagnostics and increased understanding of the underlying mechanisms of cognitive disorders	The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders	Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimers disease, progressive supranuclear palsy,frontotemporal dementia, corticobasal degeneration and mild cognitive impairment. MedDRA version: 19.1;Level: PT;Classification code 10053643;Term: Neurodegenerative disorder;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 19.1;Classification code 10012267;Term: Dementia;Classification code 10067889;Term: Dementia with Lewy bodies;Level: HLGT;Classification code 10028037;Term: Movement disorders (incl parkinsonism);Classification code 10012271;Term: Dementia Alzheimer's type;Level: HLT;Classification code 10001897;Term: Alzheimer's disease (incl subtypes);Level: LLT;Classification code 10009846;Term: Cognitive impairment;Classification code 10048598;Term: Cognitive disorders;Classification code 10001896;Term: Alzheimer's disease;Classification code 10012285;Term: Dementia due to Pick's disease;Classification code 10036813;Term: Progressive supranuclear palsy;Classification code 10074616;Term: Prodromal Alzheimer's;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]	Product Name: 18F-RO6958948 Trade Name: Vizamyl (flutemetamol(F-18)) Product Name: Vizamyl	Skåne University Hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Sweden
3	NCT02736695 (ClinicalTrials.gov)	July 2016	7/4/2016	Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia	Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and FTD	Primary Progressive Aphasia;Behavioral Variant of Frontotemporal Dementia;Frontotemporal Dementia, Behavioral Variant	Drug: F-18 AV 1451	Mayo Clinic	NULL	Recruiting	18 Years	N/A	All	200	N/A	United States
4	NCT01623284 (ClinicalTrials.gov)	March 2010	7/6/2012	PiB PET Scanning in Speech and Language Based Dementias	PiB PET Scanning in Speech and Language Based Dementias	PPA;Primary Progressive Aphasia;Aphasia;Non-fluent Aphasia;Semantic Dementia;Apraxia of Speech;Primary Progressive Nonfluent Aphasia;Progressive Aphasia	Drug: C-11 PiB;Drug: F-18 FDG	Mayo Clinic	NULL	Completed	18 Years	N/A	Both	168	Phase 1	United States
5	NCT00950430 (ClinicalTrials.gov)	April 2008	29/7/2009	Imaging of Brain Amyloid Plaques in the Aging Population	Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia	Alzheimer's Disease;Dementia With Lewy Bodies;Frontotemporal Dementia;Vascular Dementia	Drug: Pittsburgh Compound B (C-11 PiB);Drug: F-18 FDG;Drug: Tau (18-F-AV-1451)	Mayo Clinic	National Institute on Aging (NIA)	Enrolling by invitation	30 Years	100 Years	All	8000	Phase 4	United States